Skip to main content
. Author manuscript; available in PMC: 2018 Oct 5.
Published in final edited form as: N Engl J Med. 2018 Mar 21;378(14):1277–1290. doi: 10.1056/NEJMoa1712126

Figure 3. Health-Related Quality of Life in IMDC Intermediate- and Poor-Risk Patients.

Figure 3

Scores on the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI-19) range from 0 to 76, with higher scores indicating fewer symptoms. Only time points for which data were available for five or more patients are shown. The number at risk shows the number of randomly assigned patients who were in the trial at each respective time point. I bars indicate standard errors.